Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …

The myelodysplastic syndromes (MDSs) are common, acquired, clinically challenging
hematologic conditions that are characterized by bone marrow failure and a risk of …

Despite multiple disparate prognostic risk analysis systems for evaluating clinical outcome
for patients with myelodysplastic syndrome (MDS), imprecision persists with such analyses …

Purpose The karyotype is a strong independent prognostic factor in myelodysplastic
syndromes (MDS). Since the implementation of the International Prognostic Scoring System …

Purpose The aims of this study were to identify the most significant prognostic factors in
myelodysplastic syndromes (MDS) taking into account both their values at clinical onset and …

Purpose The aim of this study was to evaluate the prognostic value of the WHO proposal, to
assess the role of the main prognostic factors in myelodysplastic syndromes (MDSs) …

Well received in its first edition, Survival Analysis: A Practical Approach is completely revised
to provide an accessible and practical guide to survival analysis techniques in diverse …

Bone marrow transplantation (BMT) can cure myelodysplastic syndrome (MDS), although
transplantation carries significant risks of morbidity and mortality. Because the optimal timing …

Purpose Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders that are
more common in patients aged≥ 60 years and are incurable with conventional therapies …

Chronic myelomonocytic leukemia (CMML) is a hematologic malignancy characterized by
wide heterogeneity of clinical presentation and course. CMML shares myelodysplastic …